These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31383250)

  • 41. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
    Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
    J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
    Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.
    Jimi E; Akiyama S; Tsurukai T; Okahashi N; Kobayashi K; Udagawa N; Nishihara T; Takahashi N; Suda T
    J Immunol; 1999 Jul; 163(1):434-42. PubMed ID: 10384146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
    Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
    Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Signaling crosstalk between RANKL and interferons in osteoclast differentiation.
    Takayanagi H; Kim S; Taniguchi T
    Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S227-32. PubMed ID: 12110142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation.
    Zawawi MS; Dharmapatni AA; Cantley MD; McHugh KP; Haynes DR; Crotti TN
    Biochem Biophys Res Commun; 2012 Oct; 427(2):404-9. PubMed ID: 23000414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.
    Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N
    Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
    Merle B; Itzstein C; Delmas PD; Chenu C
    J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL.
    Kawaida R; Ohtsuka T; Okutsu J; Takahashi T; Kadono Y; Oda H; Hikita A; Nakamura K; Tanaka S; Furukawa H
    J Exp Med; 2003 Apr; 197(8):1029-35. PubMed ID: 12707301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. G Protein-Coupled Receptor 120 Signaling Negatively Regulates Osteoclast Differentiation, Survival, and Function.
    Kim HJ; Yoon HJ; Kim BK; Kang WY; Seong SJ; Lim MS; Kim SY; Yoon YR
    J Cell Physiol; 2016 Apr; 231(4):844-51. PubMed ID: 26280807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Actin-binding LIM protein 1 regulates receptor activator of NF-κB ligand-mediated osteoclast differentiation and motility.
    Jin SH; Kim H; Gu DR; Park KH; Lee YR; Choi Y; Lee SH
    BMB Rep; 2018 Jul; 51(7):356-361. PubMed ID: 29921413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
    Voronov I; Heersche JN; Casper RF; Tenenbaum HC; Manolson MF
    Biochem Pharmacol; 2005 Jul; 70(2):300-7. PubMed ID: 15919055
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
    Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
    Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
    [TBL] [Abstract][Full Text] [Related]  

  • 56. c-myc is required for osteoclast differentiation.
    Battaglino R; Kim D; Fu J; Vaage B; Fu XY; Stashenko P
    J Bone Miner Res; 2002 May; 17(5):763-73. PubMed ID: 12009006
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
    Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
    Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro.
    Yamaguchi M; Uchiyama S
    Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
    Tsujisawa T; Inoue H; Nishihara T
    J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
    Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
    J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.